BeiGene Gets FDA Orphan Designation in Waldenstrom Macroglobulinemia Treatment
TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $260
BeiGene (BGNE) Gets a Buy From TD Cowen
BeiGene: Promising Growth Trajectory and Investment Opportunity Backed by Strong Product Pipeline and Robust Financials
Selected announcements | Ping An Insurance's original premium income in the current year is nearly 800 billion yuan; GANFENGLITHIUM's Goulamina spodumene project phase one has officially gone into production.
In the first 11 months, New China Life Insurance accumulated original insurance premium income of 163.1663 billion yuan, a year-on-year increase of 2.2%; Ideal Autos granted a total of 3.94697 million restricted stock units.
BEIGENE (06160.HK) issued 1.3 million shares due to the exercise of stock options.
Gelonghui reported on December 16 that BEIGENE (06160.HK) announced the issuance of 1.3 million ordinary shares due to a Director exercising stock options on December 14, 2024.
Just Care Bears : I thought there’s a FDA approval going on on this today no news yet
Claudius NJIE Just Care Bears : yes good news is coming.
Claudius NJIE : pls run to at least 50